Xenetic Biosciences
NASDAQ: XBIOFramingham, US · Nevada corporation
Find your way into Xenetic Biosciences
369 people in our graph share verified history with the Xenetic Biosciences team — schools, employers, funds. One of them is your warm intro.
Raoul Oscar Fianounlockedknows Jeffrey Eisenberg · together at YPO (overlapped)
×5knows the team · via The Wharton School
knows the team · via YPO
×5knows the team · via Columbia Law School
Xenetic Biosciences is a biopharmaceutical company developing immuno-oncology technologies for hard-to-treat cancers. Its DNase platform targets neutrophil extracellular traps (NETs) to improve existing treatments, with a systemic DNase program being advanced into the clinic as an adjunctive therapy for pancreatic carcinoma and other solid tumors.
Founders & leadership
CL
Curtis LockshininVice President, Research & OperationsCurtis Lockshin served as Vice President of Research and Operations at Xenetic Biosciences, a biopharmaceutical company focused on oncology therapeutics, and previously held roles including Vice President of Corporate R&D Initiatives at OPKO Health and President and CEO of Guardum Pharmaceuticals.
JE
Jeffrey EisenberginChief Executive Officer and Board Member2017–2024Jeffrey Eisenberg served as general counsel and later CEO of a 700-employee Nasdaq-listed company, and previously led the U.S. subsidiary of a Japan-based publicly traded pharmaceutical firm following a $450 million acquisition. He holds a background in corporate and securities law.
JP
James ParslowExecutive
RK
Roman KnyazevNamed on SEC filing
AL
Adam LogalNamed on SEC filing
JC
James CallawayNamed on SEC filing
FD
Firdaus DastoorNamed on SEC filing
DG
Dmitry GenkinNamed on SEC filing
Board
RK
Roger KornbergBoard director
Reported raises · per SEC filings
Form D private placements$17.6M disclosed across 5 rounds · 2019–2022
▶$488.8KraisedOct 2022 · 1 investors · BiotechnologyRule 506(b)
▶$488.8KraisedOct 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Curtis LockshinExecutive Officer
- James ParslowExecutive Officer
- James CallawayDirector
- Firdaus DastoorDirector
- Grigory BorisenkoDirector
- Jeffrey EisenbergExecutive Officer, Director
- Adam LogalDirector
- Alexey VinogradovDirector
- Roger KornbergDirector
- Offering amount
- $488.8K
- Amount sold
- $488.8K
- First sale
- Oct 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$866.3KraisedMay 2022 · 2 investors · BiotechnologyRule 506(b)
▶$866.3KraisedMay 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James CallawayDirector
- Curtis LockshinExecutive Officer
- Grigory BorisenkoDirector
- Jeffrey EisenbergExecutive Officer, Director
- James ParslowExecutive Officer
- Roger KornbergDirector
- Adam LogalDirector
- Firdaus DastoorDirector
- Alexey VinogradovDirector
- Offering amount
- $866.3K
- Amount sold
- $866.3K
- First sale
- Apr 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$12.5MraisedAug 2021 · 1 investors · BiotechnologyRule 506(b)
▶$12.5MraisedAug 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam LogalDirector
- Jeffrey EisenbergExecutive Officer, Director
- James CallawayDirector
- James ParslowExecutive Officer
- Curtis LockshinExecutive Officer
- Alexey VinogradovDirector
- Roger KornbergDirector
- Firdaus DastoorDirector
- Grigory BorisenkoDirector
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- Sales commissions
- $875K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2021
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$251.5KraisedJul 2019 · 3 investors · BiotechnologyRule 506(b)
▶$251.5KraisedJul 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James ParslowExecutive Officer
- Adam LogalDirector
- Curtis LockshinDirector
- Roger KornbergDirector
- Roman KnyazevDirector
- Dmitry GenkinDirector
- Firdaus DastoorDirector
- James CallawayDirector
- Jeffrey EisenbergExecutive Officer, Director
- Offering amount
- $251.5K
- Amount sold
- $251.5K
- First sale
- Jul 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.5MraisedMar 2019 · 3 investors · BiotechnologyRule 506(b)
▶$3.5MraisedMar 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roman KnyazevDirector
- Roger KornbergDirector
- Curtis LockshinExecutive Officer
- Adam LogalDirector
- James CallawayDirector
- Jeffrey EisenbergExecutive Officer, Director
- Firdaus DastoorDirector
- James ParslowExecutive Officer
- Dmitry GenkinDirector
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- Finders' fees
- $216.8K
- Placement agents
- Maxim Group LLC
- First sale
- Mar 2019
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$34.2Mvaluation at IPONov 2016 · $4.13/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 2
by search overlap
Robinhood16 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits15 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Xenetic Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss — TradingView Newstradingview.com · Aug 2026Frequently asked questions
- What does Xenetic Biosciences do?
- Xenetic Biosciences is a biopharmaceutical company developing immuno-oncology technologies for hard-to-treat cancers. Its DNase platform targets neutrophil extracellular traps (NETs) to improve existing treatments, with a systemic DNase program being advanced into the clinic as an adjunctive therapy for pancreatic carcinoma and other solid tumors.
- How much funding has Xenetic Biosciences raised?
- Xenetic Biosciences has disclosed $17.6M raised across 5 rounds.
- Where is Xenetic Biosciences headquartered?
- Xenetic Biosciences is headquartered in Framingham, US.